To evaluate DNA methylation (DNAm) of CpGs annotated to genes for microRNAs (miRNAs) previously implicated in cardiovascular disease (CVD) and preeclampsia (PE) across all trimesters in PE case and normotensive control pregnancies. We leveraged data from an exploratory observational, longitudinal, case-control study of PE cases (n=28) and normotensive controls (n=28) individually matched on self-identified race, pre-pregnancy BMI, smoking status and gestational age at sample collection. The Human miRNA Disease Database was used to generate a candidate list of 172 miRNAs previously implicated in CVD and in PE. CpGs annotated to candidate miRNAs were extracted from epigenome-wide DNAm data collected via Infinium MethylationEPICBeadchip from serial blood samples during the three trimesters of pregnancy. Trimester-specific conditional logistic regression was used to evaluate the association between PE status and miRNA DNAm while controlling for maternal age. Analyses were performed with and without adjustment for cell type heterogeneity (CTH). Raw p-values < 0.05 were considered suggestive for this study. Among the 135 CpGs annotated to candidate miRNAs available for analysis, eight suggestive associations were observed. Specifically, DNAm of cg02999711 (MIR135B), cg26160460 (MIR181A1; MIR181B1), and cg05348084 (MIR376A1; MIR376B) in Trimester 1; cg09494646 (MIR33B), cg09559882 (MIR330), and cg14910227 (MIR495) in Trimester 2; and cg09805692 (MIR451) and cg22420044 (MIR25) in Trimester 3 were associated with PE status. Associations at four CpGs (bolded above) were consistent in both unadjusted and CTH-adjusted analyses. Findings from this exploratory study demonstrate potential differences in miRNA-associated DNAm by PE status. It is possible that aberrant levels of these particular miRNAs in CVD/PE are related to differential DNAm. Follow-up work in larger samples may provide insight into PE pathophysiology, which could inform future clinical interventions.